Evidence mapPaperPMID 42404869Full record

ArticleKidney international reports2026

Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria.

Fenglei Si, Yue Shu, Chen Tang, Jing Huang, Pei Chen, Jicheng Lv, Li Zhu, Sufang Shi, Xujie Zhou, Hong Zhang and 3 more

Abstract read
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Fenglei SiRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Yue ShuRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Chen TangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Jing HuangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Pei ChenRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Jicheng LvRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Li ZhuRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Sufang ShiRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Xujie ZhouRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Hong ZhangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Minghui ZhaoRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Zhao CuiRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Lijun LiuRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antinephrin autoantibodies are detectable in podocytopathies such as minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS); however, their prevalence and clinical relevance in IgA nephropathy (IgAN) with nephrotic-range proteinuria (NRP) and nephrotic syndrome (NS) are unclear. Methods: This single-center retrospective study enrolled 234 adults with biopsy-proven IgAN and NRP (≥ 3.5 g/d) from 2003 to 2020. Plasma antinephrin IgG and IgM were measured using enzyme-linked immunosorbent assay. Prespecified subgroups included NS ( Results: Overall antinephrin seropositivity was 8% (IgG: 6%, IgM: 2%). The seropositivity rate was 35% in patients with MCD versus 6% in those without. In patients with NS, seropositivity was 14%; rates were 35% with and 10% without MCD. Seropositive patients had heavier proteinuria (median: 8.1 vs. 4.9 g/d), lower serum albumin (21.9 ± 6.5 vs. 31.0 ± 7.2 g/l), fewer urinary red blood cells (RBCs), and similar estimated glomerular filtration rate (eGFR). Their biopsies showed milder chronic lesions (more M0/S0/T0). Seropositive patients more often received glucocorticoids and achieved higher complete remission (CR) rates (67% vs. 30% overall; 80% vs. 43% within NS) and fewer composite renal endpoints (0% vs. 28%). Multivariable analysis showed that antinephrin positivity was associated with a trend toward higher CR rates. Conclusion: Circulating antinephrin antibodies mark a podocytopathy-like phenotype in IgAN with MCD (MCD-IgAN) and define a distinct NS phenotype in patients with IgAN without overt podocytopathy. Targeted serologic testing could facilitate subgroup identification and guide tailored management.

Indexed as

IgA nephropathyminimal change diseasenephrinnephrotic syndromepodocytopathy

Identifiers

PMID42404869
PMCPMC13329496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.